Castellani Statement on Prescription Drug Costs
Washington, D.C. (May 29, 2014) – The Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John Castellani today released the following statement on the cost and value of medicines:Continue reading
Casa Grande, Arizona—Bio-agriculture company, PanAridus, announced today they have tripled the size of their research and extraction departments since the beginning of the year, bringing significantly increased capabilities for extracting high grade natural rubber from their proprietary strains of guayule.Continue reading
2013 will soon take its place in the history books with fireworks and strains of Auld Lang Syne.
As 2014 approaches, let’s look into our crystal ball for some predictions of what the new year may have in store…Continue reading
Genentech was named the winner of the Corporate Award for its consistent and impressive record in breakthrough research and innovation at The Economist’s Innovation Awards on Monday November 25th, 2013.
The Corporate award celebrates Genentech’s track record in research and innovation. Genentech was founded by biochemist Herbert Boyer and venture capitalist Robert Swanson in 1976. It has been a wholly owned subsidiary of the Roche Group since 2009. Widely considered the founder of the biotech industry, the company changed the face of medicine when it became the first to scale up protein-manufacturing from the small quantities used for research to the much larger quantities needed to treat patients. The firm’s achievements include the development of the first recombinant DNA medicine ever marketed, the first targeted medicine approved to treat cancer and the first medicine shown to improve vision in the most common cause of blindness in adults.
Genentech’s research scientists have earned more than 10,500 patents and brought breakthrough medicines to people with serious diseases such as cystic fibrosis, cancer, rheumatoid arthritis and stroke. Overall, it has 35 medicines on the market and at least 30 more in clinical development. In 2012, sales of Genentech’s medicines in the United States were CHF13.856 billion.
Patrick O’Hara Also is the 1st Indianan to be Implanted with the SynCardia Heart and the 1st Discharged From the Hospital Without a Human Heart, Thanks to the Freedom® Portable DriverContinue reading
SAN DIEGO, CA and PHOENIX, AZ–(Marketwired – Nov 12, 2013) – SGB Inc., an agricultural biotechnology company, and Yulex Corporation, a biomaterial company, announced today a collaboration to establish a genomics and molecular breeding platform focused on accelerating the crop improvement of Guayule as a sustainable source of biorubber that can replace traditional tropical or petroleum-based rubber for medical, consumer and industrial markets.Continue reading
Celebration Stem Cell Centre, an AABB accredited and FDA registered public and private cord blood bank located in Gilbert, AZ is actively seeking a Medical Director.
Candidates must be a licensed physician that is qualified by training or experience in bone marrow and cord blood transplantation. The Medical Director shall have responsibility and authority for all medical activities related to procurement, processing, and provision of the cellular therapy products and related services and to ensure that these activities are compliant with AABB, FDA and NMDP requirements. The Medical Director will work closely with the current Laboratory Director and Quality Director in respect to the following responsibilities:
- Review and approval of Standard Operating Procedures (SOPs)
- Review of Nonconforming Products
- Medical Review of donor records and test results prior to product release
- Review of Proficiency testing results
- Review of validation data of new processes/procedures
- Review of Processing data when applicable
- Participation in Quarterly Quality Meetings
- Participate in Continuing Education Relevant to cord blood
All qualified individuals are encouraged to apply for this position. Please send a copy of your C.V. and cover letter to email@example.com.
FDA Approves Gazyva™ (Obinutuzumab) for People With Previously Untreated Chronic Lymphocytic Leukemia (CLL)Continue reading
Simulation Technology Improves Medical Education, Creates JobsContinue reading